

**Freedom of Information Request: 0109**

University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1<sup>st</sup> April 2018. Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust this response has been provided by hospital site.

**Queen Elizabeth Hospital Birmingham**

**I have a FOI request with regards to Cancer treatment within your organisation**

**1 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Non-small cell Lung Cancer (NSCLC) with the following:**

- Paclitaxel**
- Gemcitabine**
- Osimertinib**
- Carboplatin and Pemetrexed**
- Cisplatin and Pemetrexed**
- Pembrolizumab monotherapy**
- Pembrolizumab in combination**
- Atezolizumab**
- Nivolumab**
- Other active systemic anti-cancer therapy**

drugs	Patient
Atezolizumab	6
Gemcitabine	12
Osimertinib	4
Paclitaxel	1
Carboplatin and Pemetrexed	17
Cisplatin and Pemetrexed	10
Pembrolizumab monotherapy	26
Pembrolizumab in combination	12

**2a – Does your Health Trust participate in any ongoing clinical trails for the treatment of Metastatic Non Small Cell Lung cancer patients ? Yes**

**2b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ? 23**

NATIONAL LUNG MATRIX TRIAL  
ASTVAC2  
IMPOWER 030 GO40241  
CA027002

**3 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the following:**

**Cetuximab not in combination with FOLFIRIE or FOLOX**

**Cetuximab in combination with FOLFIRI**

**Cetuximab in combination with FOLFOX**

**Panitumumab not in combination with FOLFIRI or FOLFOX**

**Panitumumab in combination with FOLFIRI**

**Panitumumab in combination with FOLFOX**

**Nivolumab**

**Aflibercept**

**Bevacizumab**

**Ramucirumab**

**Regorafenib**

**Sorafenib**

**Other active systemic anti-cancer therapy (eg 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU)**

Drugs	Patient
Bevacizumab	1
Cetuximab	10
Fluorouracil	99
Irinotecan	40
Oxaliplatin	64
Uracil	99
Cetuximab not in combination with FOLFIRIE or FOLOX	0
Cetuximab not in combination with FOLFIRIE	0

**3a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Colorectal cancer patients ? Yes**

**3b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ? 281**

FOCUS4

**4 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Head and Neck Cancer (Squamous Cell Carcinoma)? 67**

**4a – If your Trust is able to split these patients, how many are locally advanced and how many are recurrent and or metastatic Head and Neck Cancer patients ?**

**Locally advanced**

**Recurrent metastatic**

**Unable to split**

We do not hold this information

**4b – Of the Head and Neck cancer patients please split by their current drug treatment (if you are unable to split by locally advanced and recurrent please state the total)**

**Carboplatin (only or in combination with 5-FU)**

**Cisplatin (only or in combination with 5-FU)**

**Cetuximab with / without chemotherapy**

**Cetuximab with radiotherapy**

**Pembrolizumab monotherapy**

**Pembrolizumab with chemotherapy**

**Nivolumab**

**Docetaxel (only or in combination with 5-FU)**

**Fluorouracil (5-FU)**

**Radiotherapy only**

**Other**

We do not hold this information

**4c – Does your Health Trust participate in any ongoing clinical trials for the treatment of Head and Neck cancer patients ? yes**

**4d – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ? 151**

WISTERIA RG\_15-139

CHECKMATE 651 CA209-651

R2810-ONC-1655

D5330C00007 (closed June 2019)

PATHOS

SCORES (closed June 2019)

COMPARE

NIMRAD

**5 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Urothelial Carcinoma UCC) with the following:**

**Cisplatin single agent**

**Cisplatin in combination with another agent**

**Carboplatin single agent**

**Carboplatin in combination with another agent**

**Nivolumab**

**Pembrolizumab**

**Atezolizumab**

**Other active systemic anti-cancer therapy**

drugs	Patient
Cisplatin single agent	11
Cisplatin single agent	2
Carboplatin single agent	2
Carboplatin single agent	1
Pembrolizumab	5

**5a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Urothelial Carcinoma patients ? Yes**

**5b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ? 9**

POTOMAC D419JC00001  
INCB54828-201

**Heartlands, Good Hope and Solihull Hospital**

**I have a FOI request with regards to Cancer treatment within your organisation**

**1 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Non-small cell Lung Cancer (NSCLC) with the following:**

**Paclitaxel- 1**

**Gemcitabine - 6**

**Osimertinib - 2**

**Carboplatin and Pemetrexed - 2**

**Cisplatin and Pemetrexed - 1**

**Pembrolizumab monotherapy - 9**

**Pembrolizumab in combination -4**

**Atezolizumab - 7**

**Nivolumab -1**

**Other active systemic anti-cancer therapy** – Unable to answer with data available.

**2a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Non Small Cell Lung cancer patients? Yes**

**2b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials? 82**

FOxTROT – Fluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improves outcome in high-risk operable colon cancer.

**3 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the following:**

**Cetuximab not in combination with FOLFIRIE or FOLOX - 2**

**Cetuximab in combination with FOLFIRI - 12**

**Cetuximab in combination with FOLFOX - 5**

**Panitumumab not in combination with FOLFIRI or FOLFOX - 1**

**Panitumumab in combination with FOLFIRI - 1**

**Panitumumab in combination with FOLFOX - 0**

**Nivolumab - 1**

**Aflibercept - 0**

**Bevacizumab - 0**

**Ramucirumab - 0**

**Regorafenib - 0**

**Sorafenib - 0**

**Other active systemic anti-cancer therapy (eg 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU)**

Unable to answer, answer with data available.

**3a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Colorectal cancer patients? Yes**

**3b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials? 15**

Randomised Phase III Colorectal Cancer Study with 3 Treatment Arms

A Phase III, open-label, multicenter, three-arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy vs. regorafenib in patients with previously treated unresectable

**4 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Head and Neck Cancer (Squamous Cell Carcinoma)?**

We do not treat head and neck cancers at Heartlands, Good Hope and Solihull.

**4a – If your Trust is able to split these patients, how many are locally advanced and how many are recurrent and or metastatic Head and Neck Cancer patients ?**

Locally advanced – N/A

Recurrent metastatic – N/A

Unable to split – N/A

**4b – Of the Head and Neck cancer patients please split by their current drug treatment (if you are unable to split by locally advanced and recurrent please state the total)**

Carboplatin (only or in combination with 5-FU) – N/A

Cisplatin (only or in combination with 5-FU) – N/A

Cetuximab with / without chemotherapy – N/A

Cetuximab with radiotherapy – N/A

Pembrolizumab monotherapy – N/A

Pembrolizumab with chemotherapy – N/A

Nivolumab – N/A

Docetaxel (only or in combination with 5-FU) – N/A

Fluorouracil (5-FU) – N/A

Radiotherapy only – N/A

Other – N/A

**4c – Does your Health Trust participate in any ongoing clinical trials for the treatment of Head and Neck cancer patients? No**

**4d – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials? NA**

**5 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Urothelial Carcinoma UCC) with the following:**

Cisplatin single agent - 0

Cisplatin in combination with another agent - 1

Carboplatin single agent - 0

Carboplatin in combination with another agent - 0

Nivolumab - 0

Pembrolizumab - 2

Atezolizumab - 0

**Other active systemic anti-cancer therapy** - Unable to answer, answer with data available.

**5a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Urothelial Carcinoma patients? Yes**

**5b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ? 1**

A Phase III Study of Pembrolizumab vs. Chemotherapy in MSI-H or dMMR S